CClinicalTrials.gg
CompletedNCT03449459PAEANUpdated Jun 23, 2022

Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract

An Early Phase 1 interventional study of oral probiotics and aerosol inhaled amikacin in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Shanghai Zhongshan Hospital. Completed at 3 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-06-23.

Sponsored by Shanghai Zhongshan Hospital · Early Phase 1, Interventional, and Prevention

Phase
Early Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The colonization of potential pathogenic bacteria in lower respiratory tract is thought to be accountable for acute exacerbation in subjects with moderate to severe COPD. However, there is no accepted therapy for patients with COPD to remove the colonized bacteria in lower respiratory tract. Therefore, we plan to perform a multi-center, randomized, controlled trial to study the efficacy and safety of oral probiotics, aerosol inhaled amikacin or combined vaccination to decolonize bacteria in lower respiratory tract and prevent acute exacerbation of COPD.

Read the detailed description

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by incomplete reversible airflow limitation, small airway obstruction and alveolar structural damage. About 3 million patients die from COPD every year around the world. The prevalence of COPD in Chinese people over the age of 40 is as high as 12 % and has risen by 50 % in the past nine years.

Acute exacerbation is the leading cause of death in patients with COPD , and accounts for a majority of expenditure of COPD management. The colonization of potential pathogenic bacteria in the lower respiratory tract is an important cause of the acute exacerbation especially in patients with moderate and severe COPD.

Some clinical studies show that aerosol inhaled antibiotics is promising in reducing acute exacerbation, but these exploratory studies have some defects so that they can't back up for the clinical application of aerosol inhaled antibiotics. Amikacin, a kind of aminoglycosides, is sensitive to the common pathogens of acute exacerbation of COPD in China. Therefore it is necessary to carry out a clinical trial to verify its efficacy and safety in pathogen decolonization and prevention of acute exacerbation.

In addition, owing to bacterial resistance and insufficient antibiotics concentration in lower respiratory tract, developing new antibacterial materials is necessary. Oral probiotics is an another way to regulate the bacterial load and inflammatory response in lower respiratory tract, which has been proven to effectively prevent acute exacerbation in cystic fibrosis and childhood asthma. Likewise, airway bacterial burden and inflammation are two main mechanisms of acute exacerbation in COPD. Hence, considering its convenience and safety of oral probiotics, we perform a trial to make clinical evaluation for it.

What's more, influenza and streptococcus pneumoniae vaccines are separately recommended for patients with COPD in the Global Initiative for Chronic Obstructive Pulmonary Disease(GOLD), but there have been no studies on the effects of combined vaccination on bacterial decolonization in lower respiratory tract or on the prevention of acute exacerbation.

Effects of these above methods on the decolonization of potential pathogenic bacteria in lower respiratory tract and the inflammatory reaction are not clear. Therefore, we plan to perform a multi-center, randomized, controlled trial to study the efficacy and safety of oral probiotics, aerosol inhaled amikacin or combined vaccination to decolonize bacteria in lower respiratory tract and prevent acute exacerbation of COPD.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • chronic obstructive pulmonary disease
  • aerosol inhaled amikacin
  • oral probiotics
  • combined influenza and pneumococcal vaccine inoculation
  • bacterial decolonization in lower respiratory tract
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Written informed consent must be obtained before any assessment is performed
  2. Male or female adults aged 18-65 years
  3. Diagnosed with COPD according to GOLD 2016 (The ratio of post-bronchodilator forced expiratory volume in 1 second (FEV1) to force vital capacity (FVC)\<0.70 with the use of salbutamol 400ug)
  4. Moderate to very severe airflow limitation (post-bronchodilator FEV1 \< 80% of the predicted normal value)
  5. A documented history of at least 2 COPD exacerbation in the previous 12 months that required treatment with systemic glucocorticoids and/or antibiotics, or at least 1 exacerbation in the previous 12 months that requires hospitalization.
  6. In the stable stage of COPD

Exclusion criteria

Exclusion Criteria:

  1. Patients who have clinically significant and chronic hepatic, renal, cardiovascular and gastrointestinal abnormalities or malignant tumor (except for lung cancer) which could interfere with the assessment of the efficacy and safety of the study treatment
  2. Patients who are in critical conditions
  3. Patients who have had a COPD exacerbation that required treatment with antibiotics and/or systemic corticosteroids or an acute exacerbation of any other diseases in the 4 weeks prior to screening
  4. Patients with concomitant pulmonary disease (including but not limited to bronchiectasis, interstitial lung disease, asthma)
  5. Patients who are highly likely to be lost during the 3-month treatment and the 1-year follow up
  6. Pregnant or nursing (lactating) women
  7. Patients who have been vaccinated against influenza in the current year, or against Streptococcus pneumoniae within five years, or have vaccination contraindications
  8. Patients who are allergic to amikacin or other aminoglycosides
  9. Patients who have participated in any interventional clinical trials in the three months prior to screening
  10. Patients with mental diseases or cognitive disorders which could interfere with treatment and follow-up
04

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    oral probiotics

    Dietary Supplement: oral probiotics

  • Experimental
    aerosol inhaled amikacin

    Drug: aerosol inhaled amikacin

  • Experimental
    combined vaccination

    Biological: combined vaccination

  • No intervention
    conventional therapy (blank control)

    According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease(GOLD) 2017, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long term oxygen therapy.

Interventions

  • Dietary supplementoral probiotics

    Culturelle™ DIGESTIVE HEALTH 30 CT(VCAP)(10 Billion Claim) which consists of 100% Lactobacillus rhamnosus GG, 1 tablet, q.d., for 3 months. Subjects will take conventional therapy at the same time.

  • Drugaerosol inhaled amikacin

    0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 5-7 days per month, for 3 months. In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication. Subjects will take conventional therapy at the same time.

  • Biologicalcombined vaccination

    Influenza Vaccine recommended by World Health Organization(WHO) in that year and imported 23-Valent Pneumococcal Polysaccharide Vaccine approved by China Food and Drug Administration(CFDA) are vaccinated at different body sites by professional nurses. The interval between two vaccinations is 3-5 days to avoid the overlap of adverse events. Subjects will take conventional therapy at the same time.

05

What researchers measure

Primary outcomes

  1. Time to the first COPD exacerbation

    COPD exacerbation refers to deterioration of patients' daily symptoms requiring treatment with antibiotics or systemic glucocorticoid therapy. First COPD exacerbations starting between first dose and one day after last follow-up are included.

    Time frame: 15 months

Secondary outcomes

  1. Colonization of potential pathogenic bacteria in induced sputum

    Induced sputum represents the specimen from lower respiratory tract and should be processed within six hours after collection. Sputum plugs were separated from contaminating saliva by macroscopic examination using sterile forceps. Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and Pseudomonas aeruginosa which are the top four bacteria involved in acute exacerbation of COPD are defined as potential pathogenic bacteria. Using the plate count method, when the colony number of above four bacteria is over 100 cfu/ml,we define this bacteria as colonized bacteria in lower respiratory tract.

    Time frame: Baseline, 3 months

  2. Microbiome in induced sputum

    Induced sputum represents the specimen from lower respiratory tract and should be processed within six hours after collection. Sputum plugs were separated from contaminating saliva by macroscopic examination using sterile forceps and weighed. Bacterial genomic DNA was isolated from sputum plugs of the same weight using the specific kits. The 16S bacterial ribosomal RNA genes were Polymerase Chain Reaction (PCR)-amplified with the appropriate controls against reagent contamination. Amplified DNA fragments were sequenced using the specific sequencing platform. Sequencing reads were processed and analyzed by the specific algorithm and software. The composition and diversity of microbiome are represented by major taxonomic groups at both phylum and genus levels. If necessary, Quantitative PCR for 16S rRNA gene will be performed to validate the results of sequencing. By using these methos, we can detect the microbiome's composition and its shift.

    Time frame: Baseline, 3 months

  3. Forced Expiratory Volume in 1 Second

    Change from baseline. Pulmonary function assessments were performed using centralized spirometry according to international standards. FEV1 was measured after 15 minutes of inhaling salbutamol 400ug.

    Time frame: Baseline, 3 months, 15 months

  4. COPD Assessment Test(CAT) Score

    The COPD Assessment Test (CAT) is an 8-item uni-dimensional measure of health status impairment in COPD, containing 6 grades from 0 to 5.

    Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, 15 months

  5. modified Medical Research Council(mMRC) scale

    The modified Medical Research Council scale is a simple and powerful tool to evaluate the breathlessness, containing 5 grades from 0 to 4.

    Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, 15 months

  6. serum C-reactive protein(CRP) levels

    Serum CRP level is a sensitive marker of the systemic inflammation.

    Time frame: Baseline, 3 months

  7. interleukin(IL)-6 in induced sputum

    Induced sputum represents the specimen from lower respiratory tract. Sputum supernatant was batch analysed for the cytokines IL-6 using commercial highsensitivity sandwich ELISA kits. Inflammatory factors represent local inflammation levels in lower respiratory tract.

    Time frame: Baseline, 3 months

  8. IL-8 in induced sputum

    Induced sputum represents the specimen from lower respiratory tract. Sputum supernatant was batch analysed for the cytokines IL-8 using commercial highsensitivity sandwich ELISA kits. Inflammatory factors represent local inflammation levels in lower respiratory tract.

    Time frame: Baseline, 3 months

  9. IL-1β in induced sputum

    Induced sputum represents the specimen from lower respiratory tract. Sputum supernatant was batch analysed for the cytokines IL-1β using commercial highsensitivity sandwich ELISA kits. Inflammatory factors represent local inflammation levels in lower respiratory tract.

    Time frame: Baseline, 3 months

  10. Number of Patients With Adverse Events, Serious Adverse Events, and Death

    The overall rate of adverse events reported from initiation to the last time follow-up. Some laboratory examinations, such as blood routine, hepatorenal function and electrocardiogram, are performed twice separately at baseline and completion of intervention(3 months) in order to evaluate the safety of interventions.

    Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, 15 months

06

Study locations

3 sites
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • Ruijin Hospital, Shanghai Jiao Tong University
    Shanghai, Shanghai, China
  • Shanghai Zhongshan Hospital
    Shanghai, Shanghai, China
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03449459
Lead sponsor
Shanghai Zhongshan Hospital
Collaborators
The First Affiliated Hospital of Guangzhou Medical University, Ruijin Hospital
Responsible party
Sponsor
First posted
Feb 28, 2018
Start date
Dec 1, 2018
Primary completion
Dec 1, 2020
Completion
Dec 1, 2020
Last update
Jun 23, 2022

Study contacts

Jing Zhang, MD, PhD
principal investigator · Shanghai Zhongshan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion